Better Therapeutics, Inc.

Better Therapeutics, Inc. (Nasdaq: BTTX) is a prescription digital therapeutics company focused on cardiometabolic diseases, including type 2 diabetes and hypertension. The company entered public markets in 2021 through a merger with Mountain Crest Acquisition Corp. II, a blank-check vehicle sponsored by Mountain Crest Capital LLC. The transaction brought the company onto Nasdaq under the BTTX ticker within the broader healthcare technology and digital therapeutics sector. In February 2024, the company filed an amended registration statement (Form S-1/A, accession 0001193125-24-024856), reflecting continued regulatory and corporate activity following its de-SPAC transition. Sign up for SpacDesk to access the full filing history, deal timelines, and sponsor analytics on Better Therapeutics and hundreds of other de-SPAC companies.